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Abstract (250) 
Background: Myocardial scar is associated with adverse cardiac outcomes. The Selvester QRS-
score was developed to estimate myocardial scar from the 12-lead ECG, but its manual 
calculation is difficult. An automatically computed QRS-score would allow identification of patients 
with myocardial scar and an increased risk of mortality.  
Objectives: To assess the diagnostic and prognostic value of the automatically computed QRS-
score.  
Methods: The diagnostic value of the QRS-score computed automatically from a standard digital 
12-lead was prospectively assessed in 2’742 patients with suspected myocardial ischemia referred 
for myocardial perfusion imaging (MPI). The prognostic value of the QRS-score was then 
prospectively tested in 1’151 consecutive patients presenting to the emergency department (ED) 
with suspected acute heart failure (AHF). 
Results: Overall, the QRS-score was significantly higher in patients with more extensive 
myocardial scar: the median QRS-score was 3 (IQR 2-5), 4 (IQR 2-6), and 7 (IQR 4-10) for 
patients with 0%, 5-20% and >20% myocardial scar as quantified by MPI (p<0.001 for all pairwise 
comparisons). A QRS-Score ≥ 9 (n=284, 10%) predicted a large scar defined as >20% of the LV 
with a specificity of 91% (95%CI 90-92%). Regarding clinical outcomes in patients presenting to 
the ED with symptoms suggestive of AHF, mortality after 1 year was 28% in patients with a QRS-
score ≥ 3 as opposed to 20% in patients with a QRS-score <3 (p=0.001).  
Conclusions: The QRS-Score can be computed automatically from the 12-lead ECG for simple, 
non-invasive and inexpensive detection and quantification of myocardial scar and for the 
prediction of mortality.  
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Introduction 
 
Myocardial scar is associated with heart failure and worse outcome.1 Myocardial scar also 
provides the substrate for reentrant ventricular arrhythmias and sudden cardiac death.2 In order to 
improve survival and reduce morbidity, better strategies for identification and risk stratification of 
patients with heart failure and myocardial scar are an unmet clinical need.3  
The gold standard for identification and quantification of myocardial scar are cardiac imaging 
techniques such as cardiovascular myocardial resonance imaging (CMR)4 or myocardial perfusion 
imaging (MPI)5. However, these techniques have relevant limitations as risk stratification tools, 
since they are neither bedside tests nor widely available due to the costs and clinical expertise 
required. Preferably, an initial screening should involve simpler, cheaper and universally available 
tests, that may empower general practitioners and reduce the need for specialist referral, which 
could help to decrease the current fragmentation in clinical care. 
The standard 12-lead ECG is a universally available, inexpensive test that would fulfill these 
requirements. Traditionally, myocardial scar was assessed qualitatively in the 12-lead ECG 
focusing on the presence of Q-waves.6 More recently, the Selvester QRS-score was developed 
based on computer simulation.7,8 The idea of the scoring system is to detect and quantify 
myocardial scar from the 12-lead ECG by measuring changes in Q-, R-, and S-wave duration and 
amplitudes and morphologies.7,8 Later, modified criteria were suggested to be used in the 
presence of ECG confounders such as bundle branch blocks or LV hypertrophy.9 In patients with 
left ventricular (LV) systolic dysfunction and heart failure, the extent of myocardial scar as 
assessed by the QRS-score has been shown to predict survival and the progression of 
symptoms.10,11 Manual calculation of the QRS-score is difficult, tedious and may take up to 15 
minutes per ECG,12 thereby limiting its application in clinical practice. This problem could be 
overcome by the development of automated algorithms for calculation of the QRS-score using 
digital ECG data.13,14 However, to the best of our knowledge, the automated QRS score and its 
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association with the extent of myocardial scar has never been prospectively validated against an 
imaging gold-standard. 
The simple, non-invasive, and inexpensive detection and quantification of myocardial scar would 
be particularly helpful in the management of patients presenting with the two cardinal symptoms 
related to cardiac disease: chest discomfort and suspected myocardial ischemia as well as 
shortness of breath and suspected acute heart failure.	We therefore performed a diagnostic study 
in two distinct large cohorts to examine the diagnostic and prognostic value of the QRS-score. Our 
aim was to determine (a) the association of the Selvester QRS-score automatically computed from 
the standard 12-lead ECG with the extent of myocardial scar as quantified by myocardial perfusion 
imaging (MPI), and (b) the prognostic value of the QRS-score to predict all-cause mortality during 
long-term follow-up in patients presenting to the ED with shortness of breath.  
  
5 
 
 
Methods 
Patient Population Myocardial Perfusion Imaging Cohort: BASEL VIII Study 
We prospectively enrolled consecutive patients referred to the University Hospital Basel for the 
evaluation of suspected myocardial ischemia by rest/stress myocardial perfusion imaging (MPI) for 
the “Biomarkers and ECG signals in exercise-induced myocardial ischemia (BASEL VIII)” study 
(ClinicalTrials.gov registry, number NCT01838148).15,16 The authors designed the study, gathered, 
and analysed the data according to the STARD guidelines for studies of diagnostic accuracy 
(Supplemental Methods). 
 
MPI acquisition and interpretation protocol 
Patients underwent routine rest/stress imaging using either a dual isotope (201Tl for rest, 99mTc 
sestamibi for stress) MPI protocol or a protocol with 99Tc for both examinations17. A standardized, 
stepwise, and symptom-limited bicycle exercise stress testing or a pharmacological stress testing 
protocol was performed.18 MPI were evaluated by an expert team consisting of a cardiologist and 
a nuclear medicine physician and scored semi-quantitatively using a 17 segment bull’s eye 
scheme with a 5-point scale (0 = normal. 1 = mildly reduced tracer uptake. 2 = moderately reduced 
tracer uptake. 3 = severely reduced tracer uptake. 4 = no uptake).18 Summed stress scores (SSS) 
and summed rest scores (SRS) were computed by adding the scores of the 17 segments in the 
stress and rest images respectively. Left ventricular ejection fraction (LVEF) was computed from 
post-stress gated images. The adjudication of the presence or absence of myocardial scar was 
based on the number of non-reversible segments (stress-rest score combinations of 4-4, 4-3, 3-3, 
3-2, or 2-2) was summed up and used as a surrogate of the extent of myocardial scar size as 
described previously, with each non-reversible segment representing approximately 5% of 
myocardial scar.19  
 
Patient Population Acute Decompensated Heart Failure Cohort: BASEL V Study 
We prospectively enrolled patients with symptoms suggestive of acute heart failure (AHF) 
presenting to the ED of the University Hospital Basel for the ”Basics in acute shortness of breath 
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evaluation (BASEL V)” study (ClinicalTrials.gov registry, number NCT01831115).20,21 A final 
diagnosis of AHF was adjudicated by two independent cardiologists using all available information 
pertaining to the individual patient after hospital discharge applying the guidelines of the European 
Society of Cardiology3. In case of disagreement, the case was reviewed by a third cardiologist who 
decided ultimately. Enrollment was independent of renal function, but patients with terminal renal 
failure on chronic renal replacement therapy were excluded for this analysis.  
 
Follow-Up BASEL V Study 
Patients were contacted after 1 year by telephone calls or in written form. Furthermore, information 
was obtained by institutional chart review, the family physician’s records and the national registry 
on mortality. The primary prognostic endpoint was all-cause mortality during 1 year of follow-up. 
 
Ethic’s approval 
BASEL VIII and BASEL V were carried out according to the principles of the Declaration of 
Helsinki and approved by the local ethics committee. Written informed consent was obtained from 
all participating patients.  
 
Recording of digital ECGs 
Resting 12-lead ECGs were acquired prior to the exercise stress test (BASEL VIII) or during 
standard clinical assessment of patients in the ED (BASEL V) using an AT-110 or CS-200 
Excellence ECG device (Schiller AG, Baar, Switzerland). The digital ECG raw data was recorded 
using a minimal sampling rate of 500Hz, a minimal resolution of 5 µV/bit and a minimal diagnostic 
signal bandwidth of 0.05Hz to 150Hz. 
 
Principle of the Selvester QRS-score to quantify myocardial scar from the 12-lead ECG 
The Selvester QRS-score analysis protocol to quantify myocardial scar from the 12-lead ECG has 
previously been reported in detail.9,22 In brief, ECGs are first classified for confounders into the 6 
categories: left bundle branch block (LBBB), right bundle branch block (RBBB) and left anterior 
fascicular block (LAFB), isolated RBBB, isolated LAFB, left ventricular hypertrophy (LVH) or no 
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confounders. Second, points for Q-, R-, and S-wave amplitudes, durations, amplitude ratios, and 
notches in 10 of the 12 standard ECG leads (excluding leads III and aVR) are awarded according 
to the ventricular conduction/hypertrophy type. With a total of 54 criteria, a maximum QRS-score 
of 32 points can be reached, with each point representing 3% of the LV with myocardial scar. In 
addition, age and sex adjustments are made to the score criteria, as the normal limits of Q-, R-, 
and S-wave amplitudes and durations may differ by age and sex. For illustration and better 
understanding of the Selvester QRS-score, a sample scoring sheet and additional details are 
provided within the online supplemental appendix.  
 
Automated calculation of the Selvester QRS-score 
The raw data of the digital 12-lead ECG was analyzed using the Schiller ECG analysis program 
(ETM V01.12.09.00, Schiller AG, Baar, Switzerland). Automated Q-, R-, and S-amplitude and 
duration measurements along with diagnostic statement codes were extracted and used for 
analysis. The criteria used to automatically classify ECG confounder types for QRS scoring have 
been published before14 and are listed in the online supplemental appendix.  
 
Statistical analysis 
Continuous variables are presented as mean (standard deviation) or median (interquartile range 
[IQR]); categorical variables, as numbers and percentages. Differences in baseline characteristics 
between patients were assessed using the Mann-Whitney test for continuous variables and the 
Pearson Chi Square test for categorical variables. Receiver-operating-characteristic (ROC) curves 
were constructed to assess the diagnostic accuracy of the QRS-score to diagnose a myocardial 
scar as adjudicated based on MPI. Survival according to QRS-score categories was plotted in 
Kaplan-Meier curves. The log-rank test was used to assess differences in mortality between 
groups. We used univariate Cox proportional hazard analysis to compute hazard ratios and 95% 
confidence intervals of the QRS-score to predict all-cause mortality and cardiovascular re-
hospitalization. The model was further adjusted for the following established predictors of death to 
assess for independent prognostic value of the QRS-score (with dichotomous cut-points selected 
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where appropriate): age ≥ 70, gender, dyspnea NYHA IV vs. II and III vs. II, QRS duration ≥ 
120ms, creatinine ≥105 umol/l, heart rate ≥ 80 bpm and the presence of diabetes mellitus, atrial 
fibrillation or LBBB.  
All hypothesis testing was two-tailed and p-values < 0.05 were considered statistically significant. 
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 22.0 (SPSS 
Inc, Chicago, IL) and the R statistical package (MathSoft, Seattle, WA).   
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Results 
Enrolment and characteristics of patients referred for myocardial perfusion imaging 
(BASEL VIII Study) 
From January 2010 to November 2014, a total of 4’219 unselected patients undergoing evaluation 
of suspected exercise inducible myocardial ischemia by myocardial perfusion imaging (MPI) were 
prospectively enrolled. Patients without a digital 12-lead ECG were excluded from analysis 
(n=1’002), as were patients with non-specific bundle branch block (NBBB, n=99) and ventricular 
pacing (n=57), which precluded automated calculation of the QRS-Score. Furthermore, patients 
with no SRS-score available, meaning patients with only stress imaging (n=319) were excluded, 
leaving 2’742 patients for analysis (Supplemental Figure 1).  
Baseline characteristics of the patients are shown in Table 1. 32% of the patients had a history of 
myocardial infarction (MI) with a median time interval from MI to enrolment of 3.4 years (IQR 0.53-
10.5 years).  
Overall, no evidence of myocardial scar as quantified by MPI was seen in 62% of the patients. In 
32% of the patients, the extent of myocardial scar was 5-20% and in 6% of the patients, more than 
20% myocardial scar was present.  
 
Levels of the QRS-score in the MPI cohort 
The median QRS-score was 3 (IQR 2-6), representing an estimated LV scar of 9% (IQR 6-18%). 
Baseline characteristics of the patients stratified for QRS-scores ≥ or < the median QRS-score of 3 
are shown in Table 1. Patients with a QRS-score ≥ 3 more often had a history of coronary artery 
disease (CAD), MI and revascularization. The left ventricular ejection fraction (LVEF) as measured 
by MPI was significantly lower in patients with higher QRS-scores (all p-values < 0.001).  
 
 
Association of the QRS-score with the extent of myocardial scar 
As shown in Figure 1, the QRS-score was significantly higher in patients with more extensive 
myocardial scar as quantified by MPI: for patients without myocardial scar, the median QRS-score 
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was 3 (IQR 2-5), for patients with 5-20% myocardial scar, the median QRS-score was 4 (IQR 2-6), 
and for patients with more than 20% myocardial scar, the QRS-score was 7 (IQR 4-10, p < 0.001 
for all pairwise comparisons). Of all patients with myocardial scar, 89% had a QRS-score ≥1, 
resulting in a sensitivity of 94% (95%CI 90-97%) for the detection of any myocardial scar. 
Diagnostic accuracy of the QRS-score for the detection of any myocardial scar as quantified by 
the AUC was 0.60 (95%CI 0.58-0.62). For the detection of a myocardial scar > 20% the AUC was 
0.73 (95%CI 0.69-0.78). A QRS-Score ≥ 9 (n=284, 10%) predicted a large scar defined as > 20% 
of the LV with a specificity of 91% (95%CI 90-92%). 
 
Impact of ECG confounders on the association with myocardial scar  
The ECG was free of confounders in 82% of patients. Of those with ECG confounders, complete 
LBBB was present in 3.4%, combined RBBB & LAFB in 2.2%, isolated RBBB in 3.2%, isolated 
LAFB in 3.0%, and LVH in 5.8% of all cases. Presence and type of ECG confounders of cardiac 
de- and repolarization resulted in significant changes of the QRS-score. Median QRS-scores for 
the different ECG confounder groups overall and according to the extent of myocardial scar are 
shown in Table S1. Of particular note, the presence of LAFB either in isolation or in conjunction 
with RBBB resulted in higher QRS-scores compared to all other groups. 
 
Diagnostic value of the QRS-score to detect a reduced LVEF <35% 
A reduced LVEF < 35% was found in 209 patients (8%). As shown in Figure 2, the QRS-score was 
significantly higher in patients with reduced LVEF: for patients with LVEF <35%, the median QRS-
score was 5 (IQR 3-9) and for patients with more than 55% LVEF, the QRS-score was 3 (IQR 1-5, 
p < 0.001). For patients with a QRS-score ≥ 9 (10%), the specificity to detect a reduced LVEF was 
91% (95%CI 90-92%) and sensitivity was 24% (95%CI 19-31%). On the other hand, a QRS-score 
of 0 (12%) had a sensitivity of 94% (90-97%) and a specificity of 13% (95%CI 12-14%) to rule-out 
a reduced LVEF <35%.  
 
11 
 
 
Enrolment and characteristics of patients with symptoms suggestive of AHF (BASEL V 
Study) 
From September 2001 to January 2013, a total of 2’130 patients with symptoms suggestive of 
AHF presenting to the ED were prospectively enrolled. Patients without a digital 12-lead ECG 
were excluded from analysis (n=881), as were patients with NBBB (n=84) and ventricular pacing 
(n=14), leaving 1’151 patients for analysis (Figure S2). Overall, 61% of patients had a final 
adjudicated diagnosis of AHF.  
 
Levels of the QRS-score in the AHF cohort 
Overall, the median QRS-score was 3 (IQR 1-6) equal to an estimated LV scar of 9% (3-18%). 
Baseline characteristics of the patients stratified for QRS-score levels ≥ or < the median value of 3 
are shown in Table 2. Similarly, to the Basel VIII cohort, patients with higher QRS-score had more 
often a history of CAD, MI and revascularization and had significantly higher B-type natriuretic 
peptide (BNP) levels at presentation (345 vs 605 ng/l, p < 0.001). A QRS-score ≥ 3 was 
associated with a higher probability for a final adjudicated diagnosis of AHF (67% vs. 55%. 
p<0.001). 
 
Diagnostic value of the QRS-score to detect a reduced LVEF <35% in patients with 
suspected AHF 
The LVEF was assessed by transthoracic echocardiography (TTE) in 653 patients. A reduced 
LVEF < 35% was found in 21% of the patients. As shown in Figure 2, the QRS-score was 
significantly higher in patients with reduced LVEF: for patients with LVEF <35%, the median QRS-
score was 4 (IQR 2-7), for patients with 35-55% LVEF, the median QRS-score was 3 (IQR 1-6), 
and for patients with more than 55% LVEF, the QRS-score was 2 (IQR 1-5, p < 0.001).  
Similar to the results in the BASEL VIII cohort, a QRS-score ≥ 9 (11%) had specificity to detect a 
reduced LVEF by TTE of 91 % (95%CI 89-94%) with a corresponding sensitivity of 20% (95%CI 
14-28%). On the other hand, a QRS-score of 0 (18%) had a sensitivity of 89% (95%CI 82-94%) 
and a specificity of 16% (95%CI 13-20%) to rule-out a reduced LVEF <35%.  
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Prognostic value of the QRS-score for the prediction of mortality during follow-up 
During a mean follow-up time of 430 days, there were 367 deaths (32%) in the whole cohort. All-
cause mortality after 1 year was 28% in patients with a QRS-score ≥ 3 as opposed to 20% in 
patients with a QRS-score <3 in Kaplan-Meier analysis (p=0.001 Figure 3A). The difference in 
mortality could be observed as early as after 30 days with mortality rates of 9% vs. 5% in patients 
with a QRS-score ≥ 3 vs. < 3 (p=0.02). When assessing only patients with a final adjudicated 
diagnosis of AHF (61% of the overall cohort) the all-cause mortality rates at 1-year follow-up were 
32% vs. 23% for patients with a QRS-score ≥ 3 and < 3 (p = 0.01). The observation of higher 
mortality rates at 30 and 360 days in patients with a QRS-score ≥ 3 was confirmed in patients with 
and without ECG confounders present in the 12-lead ECG (Table S2). In univariable cox 
proportional hazard analysis QRS-score as a continuous variable (per 3-point increase) was 
significantly related with all-cause mortality (Hazard Ratio, 1.11, 95%CI 1.02-1.22, p=0.02). When 
using a dichotomous cut-off for presence of scar defined by the median QRS-score of ≥ 3, there 
were 48% more deaths compared to patients with a QRS-score < 3 (Hazard Ratio 1.48, 95%CI 
1.16-1.89, p=0.001). After adjusting for important clinical factors (including age, diabetes mellitus, 
dyspnea and renal failure) and ECG parameters (QRS duration, heart rate, atrial fibrillation and 
LBBB) in multivariable analysis, a QRS-score ≥ 3 remained an independent predictor of mortality 
(Hazard Ratio 1.42, 95%CI 1.10-1.83, for QRS >=3 versus <3, p=0.006, Table 3).  
 
QRS-score association with cardiovascular re-hospitalization  
During follow-up, a total of 248 patients (22%) required a re-hospitalization due to congestive heart 
failure (CHF) or another cardiac reason. There were 45% more re-hospitalizations in patients with 
a QRS-score ≥ 3 (HR 1.45, 95%CI 1.12-1.89, p=0.005, Figure 3B). The QRS-score as a 
continuous variable (per 3 points increase) was also significantly related with first occurrence of re-
hospitalization during 360 days (HR 1.18, 95%CI 1.08-1.30, p=0.001). After adjusting for clinical 
factors and ECG parameters, a QRS-score ≥ 3 was an independent predictor of re-hospitalization 
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along with the presence of atrial fibrillation, diabetes mellitus and renal failure at presentation 
(Table S3).  
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Discussion 
In two large prospective diagnostic studies, we aimed (a) to assess the association of the QRS-
score automatically computed from the 12-lead ECG with the extent of myocardial scar as 
quantified by MPI in 2742 patients and (b) to study the prognostic value of the QRS-score to 
predict mortality during long-term follow-up in 1151 patients presenting to the ED with symptoms 
suggestive of AHF.  
We report three major findings: First, QRS-scores at presentation were significantly higher in 
patients with more extensive myocardial scar on MPI. The diagnostic accuracy of the QRS-score 
for the detection of any myocardial scar on MPI as quantified by the AUC was 0.60 and increased 
to 0.73 for the detection of >20% myocardial scar. Second, higher QRS-scores predicted a 
reduced LVEF in both cohorts. A QRS-score ≥ 9 had a specificity of 91% in both cohorts to detect 
a LVEF <35%. Third, the QRS-score was a powerful predictor of all-cause mortality and re-
hospitalization in patients presenting to the ED with symptoms suggestive of AHF independent of 
important other clinical and ECG factors. All-cause mortality after 1 year was 28% in patients with 
a QRS-score ≥ 3 as opposed to 20% in patients with a QRS-score <3 (p<0.001).  
These findings extend and corroborate previous data on the possible clinical utility of the QRS-
score to predict the presence of myocardial scar.13,23–27 This study has important methodological 
strengths differentiating it from previous studies on the QRS-score, including but not limited to its 
prospective design, the automated calculation of the updated QRS scoring system, the 
applicability in the presence of traditional ECG confounders and the use of the adjusted criteria for 
age and sex. Furthermore, to the best of our knowledge, this is the largest prospective validation 
studying the association of the QRS-score with the extent of myocardial scar as quantified by a 
cardiac imaging technique. 
The diagnostic performance of the QRS-score to detect myocardial scar in this study was similar 
to that reported elsewhere using CMR.13,23–25,27 Previously, a wide range of diagnostic accuracy to 
detect myocardial scar was shown with AUC between 0.62 and 0.91.13,23,27 The reasons for this 
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variety are manifold. First, in the early beginning, Selvester and Coworkers 8,28 developed the 
QRS-score in the non-reperfusion era for acute MI in comparison to post-mortem histopathological 
analysis. It is therefore possible that the score best reflects acute scar resulting from non-
reperfused fatal myocardial infarctions rather than chronic, remodelled myocardial scar late after 
AMI. This hypothesis was further supported by CMR studies, as also stronger correlation for ECG 
estimated scar was seen in patients early after a first MI.24,26 Second, the association between the 
QRS-score and the extent of myocardial scar on MPI is more robust in patients without ECG 
confounders. Hence, the diagnostic performance of the QRS score varies depending on the 
prevalence of ECG confounders in a cohort. This proportion of ECG confounders was 18% in our 
study, and remarkably higher compared to some of the previous studies, which enrolled as little as 
9 patients (6%) with ECG confounders.29 With regards to the different subgroups of ECG 
confounders, we could confirm the previous observation that the algorithm overestimated the 
extent of myocardial scar particularly in patients with isolated LAFB or LAFB & RBBB.13,27 As 
opposed to the QRS-score in patients without ECG confounders, the modified QRS scoring 
system in the presence of conduction defects was created based on computer simulation and has 
never been validated with post-mortem analysis.9 Given that the presence of LAFB significantly 
affects leads V4-V6, Wieslander et al.27 made an attempt to modify the scoring system by excluding 
points derived from leads V4-V6 in LAFB patients, which improved the AUC for scar detection from 
0.62 to 0.67. Third, the manual calculation of the QRS-score is difficult, tedious and may take up to 
15 minutes per ECG.12 Accordingly, results were often highly operator-dependent and its 
application in clinical practice was limited. Using an automated algorithm for calculation of the 
QRS-score from digital ECG data, the method is much more robust and can be easily applied in 
clinical practice.14,30 Our study is the first to prospectively validate an automatically computed 
QRS-score against an imaging gold standard. The similar diagnostic accuracy compared to 
studies using manual calculation done by extensively trained and highly experienced ECG readers 
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is important and supports the suitability of the automated QRS score for a broad clinical 
application.13,23,27  
The extent of myocardial scar is correlated with LVEF. Accordingly, higher QRS-scores predicted 
a reduced LVEF and a QRS-score ≥ 9 had a specificity of >90% in both cohorts to detect a LVEF 
<35%. Given that current guidelines for ICD-implantation for primary prevention of sudden cardiac 
death focus predominantly on a LVEF <35%, the QRS-score may serve as a simple screening tool 
in general medical populations to identify patients potentially at risk that might benefit from further 
work-up with echocardiography.  
Beyond its diagnostic utility in the detection of myocardial scar, the QRS-score is a simple, 
inexpensive and easily implementable method for the prediction of clinical outcome. In our cohort 
of patients presenting with symptoms suggestive of AHF, those with a QRS-score above the 
median (≥3) had a 48% higher risk of mortality and a 45% higher risk of re-hospitalization due to 
cardiovascular causes within 1-year after the index presentation. This is in line with previous 
observations made in studies investigating the prognostic value of the QRS-score in various other 
settings14,23,26,31,32. Similar to our results, a recent study showed that in 100 consecutive acute MI 
patients, a QRS-score ≥ 3 at hospital discharge was associated with significantly more deaths or 
hospitalizations for heart failure during follow-up compared with a QRS-score < 3 (45% vs. 8%, p < 
0.001).32 It is important to highlight that the incremental value of the QRS-score for risk 
stratification was independent of other important clinical and ECG factors including age and QRS 
duration.  
It has to be mentioned that the QRS-score should not be seen as an alternative to imaging 
techniques. Rather, it should be used as an easily available additional screening tool for risk 
stratification in conjunction with all available other information. Particularly in the primary care 
setting, the QRS-score provides a simple, non-invasive and inexpensive tool for the general 
practitioner for the identification of patients with so far undetected myocardial scar and an 
increased risk. A QRS-score ≥ 9 in a patient with no known cardiac history should trigger referral 
17 
 
 
to a cardiologist for additional workup. Doing so, it is a tool that may empower general 
practitioners in the delineation of a personalized management plan. It is possible that a further 
improvement of its performance can be achieved by refinement of some of the less specific criteria 
of the score (54 in total).27 Our results also demonstrate that research focusing on advanced ECG 
technologies has the potential to remarkably increase the value of the surface 12-lead ECG in 
clinical cardiology.16,33 
Potential limitations of the present study merit consideration. First, it is a matter of ongoing 
discussion, which cardiac imaging modality provides the most favorable characteristics for the 
detection and quantification of a myocardial scar.34 While CMR provides higher spatial resolution 
and is therefore superior in the detection of very small myocardial scars,35 it cannot be applied in 
patients with pacemakers and defibrillators, and is challenging to apply in patients with 
claustrophobia. As MPI has important logistic advantages compared to CMR, and as a direct 
comparison of MPI versus CMR using absolute scar quantification with necropsy as reference 
standard showed comparable performance of both techniques, MPI seemed well suited for the 
purpose of the current study using a semi-quantitative assessment of the extent of myocardial 
scar.34 Second, the value of the QRS-score to predict mortality was assessed in ED patients with 
symptoms suggestive of AHF in our study. Further studies are needed to assess the prognostic 
value of the QRS-score in other patient populations, e.g. for risk stratification in the general 
population or in patients after AMI. Third, further research may improve the classification of 
borderline ECGs, e.g. the fine-tuning of the definition of LBBB.36  Fourth, it is possible that beat-to-
beat variation in the QRS complex may lead to different numbers of points to be assigned to a 
lead depending on which beat is evaluated. In order to limit bias and error, we used a computer-
generated median beat.  
In conclusion, the QRS-Score, a marker quantifying myocardial scar, can be automatically 
computed from the 12-lead ECG. It is associated with the extent of myocardial scar as quantified 
by MPI. In addition, the QRS-score independently predicts all-cause mortality in patients 
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presenting with symptoms suggestive of AHF and helps categorizing patients into those with 
reduced and normal ejection fraction. Therefore, the QRS-score provides a simple, non-invasive 
and inexpensive tool for the identification of patients at risk and thereby may be an important 
contributor in the delineation of a personalized management plan.  
19 
 
 
Acknowledgements 
The authors thank the patients who participated in the study and the staff of the Department of 
Nuclear Medicine. 
 
Funding  
This study was supported by research grants from the Swiss National Science Foundation, the 
Swiss Heart Foundation, the Cardiovascular Research Foundation Basel, the University Hospital 
Basel, Abbott. and BRAHMS. 
  
Disclosures 
Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss 
Heart Foundation, the Cardiovascular Research Foundation Basel, Abbott, Beckman Coulter, 
BRAHMS, Roche, Siemens. and the University Hospital Basel, as well as speaker honoraria from 
Abbott, ALERE, Astra Zeneca, BG Medicine, Biomerieux, Brahms, Cardiorentis, Lilly, Novartis, 
Roche, and Siemens. Dr. Reichlin has received research grants from the Goldschmidt-Jacobson 
Foundation, the Swiss National Science Foundation (PASMP3-136995) the Swiss Heart 
Foundation, the Professor Max Cloëtta Foundation, the Cardiovascular Research Foundation 
Basel, the University of Basel and the University Hospital Basel as well as speaker honoraria from 
Brahms and Roche. Dr. Twerenbold has received research support from the Swiss National 
Science Foundation (P300PB-167803/1) and speaker honoraria/consulting honoraria from Roche, 
Abbott, Siemens and Brahms. Dr. Boeddinghaus has received speaker honoraria from Siemens.  
All other authors declare that they have no conflict of interest with this study. 
 
 
 
 
20 
 
 
References 
1.  Levy D, Kenchaiah S, Larson MG, et al. Long-Term Trends in the Incidence of and Survival 
with Heart Failure. N Engl J Med. 2002;347(18):1397-1402. doi:10.1056/NEJMoa020265. 
2.  de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular 
tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic 
correlation. Circulation. 1988;77(3). 
3.  Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment 
of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed 
with the special contribution of. Eur Heart J. 2016;37(27):2129-2200. 
doi:10.1093/eurheartj/ehw128. 
4.  Schmidt A, Azevedo CF, Cheng A, et al. Infarct Tissue Heterogeneity by Magnetic 
Resonance Imaging Identifies Enhanced Cardiac Arrhythmia Susceptibility in Patients With 
Left Ventricular Dysfunction. Circulation. 2007;115(15):2006-2014. 
doi:10.1161/CIRCULATIONAHA.106.653568. 
5.  Barbagelata A, Di Carli MF, Califf RM, et al. Electrocardiographic infarct size assessment 
after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine 
(AMISTAD) trial. Am Heart J. 2005;150(4):659-665. doi:10.1016/j.ahj.2004.10.014. 
6.  Horan LG, Flowers NC, Johnson JC. Significance of the Diagnostic Q Wave of Myocardial 
Infarction. Circulation. 1971;43(3). 
7.  Selvester RH, Kalaba R, Collier CR, Bellman R, Kagiwada H. A digital computer model of 
the vectorcardiogram with distance and boundary effects: Simulated myocardial infarction. 
Am Heart J. 1967;74(6):792-808. doi:10.1016/0002-8703(67)90098-1. 
8.  Wagner GS, Freye CJ, Palmeri ST, et al. Evaluation of a QRS scoring system for estimating 
myocardial infarct size. I. Specificity and observer agreement. Circulation. 1982;65(2):342-
347. doi:10.1161/01.CIR.65.2.342. 
9.  Strauss DG, Selvester RH. The QRS complex--a biomarker that “images” the heart: QRS 
scores to quantify myocardial scar in the presence of normal and abnormal ventricular 
conduction. J Electrocardiol. 2009;42(1):85-96. doi:10.1016/j.jelectrocard.2008.07.011. 
10.  Stevenson WG, Friedman PL, Sager PT, et al. Exploring Postinfarction Reentrant 
Ventricular Tachycardia With Entrainment Mapping. J Am Coll Cardiol. 1997;29(6):1180-
1189. doi:10.1016/S0735-1097(97)00065-X. 
11.  Yokota H, Heidary S, Katikireddy CK, et al. Quantitative characterization of myocardial 
infarction by cardiovascular magnetic resonance predicts future cardiovascular events in 
patients with ischemic cardiomyopathy. J Cardiovasc Magn Reson. 2008;10(1):17. 
doi:10.1186/1532-429X-10-17. 
12.  Kojodjojo P, Tokuda M, Bohnen M, et al. Electrocardiographic left ventricular scar burden 
predicts clinical outcomes following infarct-related ventricular tachycardia ablation. Hear 
Rhythm. 2013;10(8):1119-1124. doi:10.1016/j.hrthm.2013.04.011. 
13.  Strauss DG, Selvester RH, Lima JAC, et al. ECG Quantification of Myocardial Scar in 
Cardiomyopathy Patients With or Without Conduction Defects. Circ Arrhythmia 
Electrophysiol. 2008;1(5). 
14.  Strauss DG, Mewton N, Verrier RL, et al. Screening entire health system ecg databases to 
identify patients at increased risk of death. Circ Arrhythmia Electrophysiol. 2013;6(6):1156-
1162. doi:10.1161/CIRCEP.113.000411. 
21 
 
 
15.  Tanglay Y, Twerenbold R, Lee G, et al. Incremental Value of a Single High-sensitivity 
Cardiac Troponin I Measurement to Rule Out Myocardial Ischemia. Am J Med. 
2015;128(6):638-646. doi:10.1016/j.amjmed.2015.01.009. 
16.  Wagener M, Abächerli R, Honegger U, et al. Diagnostic and Prognostic Value of Lead aVR 
During Exercise Testing in Patients Suspected of Having Myocardial Ischemia. Am J 
Cardiol. January 2017. doi:10.1016/j.amjcard.2016.11.056. 
17.  Buechel RR, Kaufmann BA, Tobler D, Wild D, Zellweger MJ. Non-invasive nuclear 
myocardial perfusion imaging improves the diagnostic yield of invasive coronary 
angiography. Eur Heart J Cardiovasc Imaging. 2015;16(8):842-847. 
doi:10.1093/ehjci/jev095. 
18.  Zellweger MJ, Maraun M, Osterhues HH, et al. Progression to Overt or Silent CAD in 
Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk: Main Findings of the 
Prospective Multicenter BARDOT Trial With a Pilot Randomized Treatment Substudy. JACC 
Cardiovasc Imaging. 2014;7(10):1001-1010. doi:10.1016/j.jcmg.2014.07.010. 
19.  Arenja N, Mueller C, Ehl NF, et al. Prevalence, extent, and independent predictors of silent 
myocardial infarction. Am J Med. 2013;126(6):515-522. doi:10.1016/j.amjmed.2012.11.028. 
20.  Reichlin T, Potocki M, Breidthardt T, et al. Diagnostic and prognostic value of uric acid in 
patients with acute dyspnea. Am J Med. 2009;122(11):1054.e7-1054.e14. 
doi:10.1016/j.amjmed.2009.04.023. 
21.  Breidthardt T, Irfan A, Klima T, et al. Pathophysiology of Lower Extremity Edema in Acute 
Heart Failure Revisited. Am J Med. 2012;125(11):1124.e1-1124.e8. 
doi:10.1016/j.amjmed.2011.12.015. 
22.  Loring Z, Chelliah S, Selvester RH, Wagner G, Strauss DG. A detailed guide for 
quantification of myocardial scar with the Selvester QRS score in the presence of 
electrocardiogram confounders. J Electrocardiol. 2011;44(5):544-554. 
doi:10.1016/j.jelectrocard.2011.06.008. 
23.  Rosengarten JA, Scott PA, Chiu OKH, Shambrook JS, Curzen NP, Morgan JM. Can QRS 
scoring predict left ventricular scar and clinical outcomes? Europace. 2013;15(7):1034-1041. 
doi:10.1093/europace/eut014. 
24.  Engblom H, Wagner GS, Setser RM, et al. Quantitative clinical assessment of chronic 
anterior myocardial infarction with delayed enhancement magnetic resonance imaging and 
QRS scoring. Am Heart J. 2003;146(2):359-366. doi:10.1016/S0002-8703(03)00187-X. 
25.  Geerse DA, Wu KC, Gorgels AP, Zimmet J, Wagner GS, Miller JM. Comparison between 
Contrast-Enhanced Magnetic Resonance Imaging and Selvester QRS Scoring System in 
Estimating Changes in Infarct Size between the Acute and Chronic Phases of Myocardial 
Infarction. Ann Noninvasive Electrocardiol. 2009;14(4):360-365. doi:10.1111/j.1542-
474X.2009.00327.x. 
26.  Strauss DG, Poole JE, Wagner GS, et al. An ECG index of myocardial scar enhances 
prediction of defibrillator shocks: An analysis of the Sudden Cardiac Death in Heart Failure 
Trial. Hear Rhythm. 2011;8(1):38-45. doi:10.1016/j.hrthm.2010.09.071. 
27.  Wieslander B, Nijveldt R, Klem I, et al. Evaluation of Selvester QRS score for use in 
presence of conduction abnormalities in a broad population. Am Heart J. 2015;170(2):346-
352. doi:10.1016/j.ahj.2015.05.005. 
28.  Ward RM, White RD, Ideker RE, et al. Evaluation of a QRS scoring system for estimating 
myocardial infarct size. Am J Cardiol. 1984;53(6):706-714. doi:10.1016/0002-
9149(84)90390-4. 
22 
 
 
29.  Weinsaft JW, Kochav JD, Afroz A, Okin PM. Q wave area for stratification of global left 
ventricular infarct size. Coron Artery Dis. 2014;25(2):138-144. 
doi:10.1097/MCA.0000000000000062. 
30.  Horáček BM, Warren JW, Albano A, et al. Development of an automated Selvester Scoring 
System for estimating the size of myocardial infarction from the electrocardiogram. J 
Electrocardiol. 2006;39(2):162-168. doi:10.1016/j.jelectrocard.2005.08.013. 
31.  Wagner GS, Freye CJ, Palmeri ST, et al. Evaluation of a QRS scoring system for estimating 
myocardial infarct size. I. Specificity and observer agreement. Circulation. 1982;65(2). 
32.  Kalogeropoulos AP, Chiladakis JA, Sihlimiris I, Koutsogiannis N, Alexopoulos D. 
Predischarge QRS Score and Risk for Heart Failure After First ST-Elevation Myocardial 
Infarction. J Card Fail. 2008;14(3):225-231. doi:10.1016/j.cardfail.2007.11.004. 
33.  Abächerli R, Twerenbold R, Boeddinghaus J, et al. Diagnostic and prognostic values of the 
V-index, a novel ECG marker quantifying spatial heterogeneity of ventricular repolarization, 
in patients with symptoms suggestive of non-ST-elevation myocardial infarction. Int J 
Cardiol. February 2017. doi:10.1016/j.ijcard.2017.01.151. 
34.  Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon 
emission computed tomography (SPECT) perfusion imaging for detection of subendocardial 
myocardial infarcts: an imaging study. Lancet (London, England). 2003;361(9355):374-379. 
doi:10.1016/S0140-6736(03)12389-6. 
35.  Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of 
myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc 
Imaging. 2011;4(2):150-156. doi:10.1016/j.jcmg.2010.11.015. 
36.  Strauss DG, Selvester RH, Wagner GS. Defining Left Bundle Branch Block in the Era of 
Cardiac Resynchronization Therapy. Am J Cardiol. 2011;107(6):927-934. 
doi:10.1016/j.amjcard.2010.11.010. 
  
23 
 
 
*MI = myocardial infarction. ECG = electrocardiogram. LBBB = left bundle branch block. RBBB = 
right bundle branch block. LAFB = left anterior fascicular block. LVH = left ventricular hypertrophy. 
MPI = myocardial perfusion imaging. LVEF = left ventricular ejection fraction. Hs-cTn = high-
Table 1 Baseline characteristics of the patients with suspected exercise inducible myocardial ischemia (BASEL VIII) 
  QRS-score  
 All patients 
(n=2’742) 
<3 
(n=1’042) 
≥3 
 (n=1’700) p-Value 
Age – years  68 (59-75) 68 (60-75) 68 (59-76) 0.90 
Male gender – no. (%) 1938 (71) 728 (70) 1210 (71) 0.49 
Risk factors – no. (%)     
Hypertension 2285 (83) 870 (83) 1415 (83) 0.90 
Hypercholesterolemia 2057 (75) 777 (75) 1280 (75) 0.70 
Diabetes 726 (27) 272 (26) 454 (27) 0.76 
Current smoking 513 (19) 180 (17) 333 (20) 0.15 
History of smoking 1175 (43) 453 (43) 722 (42) 0.63 
History – no. (%)     
Coronary artery disease 1412 (51) 504 (48) 908 (53) 0.01 
Previous MI 890 (32) 277 (27) 613 (36) <0.001 
Previous revascularization 1275 (46) 459 (44) 816 (48) 0.05 
Peripheral artery disease 285 (10) 93 (9) 192 (11) 0.06 
Previous stroke 249 (9) 94 (9) 155 (9) 0.99 
ECG findings – no. (%)     
      Q-waves 318 (12) 59 (6) 259 (15) <0.001 
      LBBB 94 (3) 35 (3) 59 (3) 0.96 
      RBBB+LAFB 60 (2) 9 (1) 51 (3) <0.001 
      RBBB 89 (3) 38 (4) 51 (3) 0.41 
      LAFB   81 (3) 4 (0) 77 (5) <0.001 
      LVH 158 (6) 74 (7) 84 (5) 0.02 
      No confounders 2260 (82) 882 (85) 1378 (81) 0.02 
Body mass index (kg/m2) 27 [25-31] 27 [25-30] 27 [25-31] 0.25 
MPI Findings     
      Presence of any scar 1050 (38) 332 (32) 718 (42) <0.001 
      Presence of > 20% scar 164 (6) 27 (3) 137 (8) <0.001 
      LVEF (%) 54 [46-63] 56 [49-64] 53 [44-62] <0.001 
Laboratory findings     
hs-cTnT. ng/L 9 [6-16] 9 [5-15] 10 [6-17] <0.001 
Chronic medication     
ASA 1792 (65) 683 (66) 1109 (65) 0.90 
Vitamin K antagonists 301 (11) 94 (9) 207 (12) 0.01 
B-blockers 1652 (60) 611 (59) 1041 (61) 0.19 
Statins 1718 (63) 655 (63) 1063 (63) 0.89 
ACEIs/ARBs 1740 (63) 649 (62) 1091 (64) 0.34 
Calcium antagonists 671 (24) 263 (25) 408 (24) 0.49 
Nitrates 288 (11) 98 (9) 190 (11) 0.16 
24 
 
 
sensitivity cardiac troponin. ASA= Acetylsalicylic acid. ACEIs/ARBs = angiotensin converting 
enzyme inhibitor/angiotensin receptor blocker. 
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Table 2 Baseline characteristics of the patients with suspected acute decompensated heart failure (BASEL V) 
 
All patients (n=1151) 
QRS-Score 
p-Value <3 
(n=534) 
≥3 
(n=617) 
Age – years 77 [66. 83] 76 [65. 83] 77 [66. 84] 0.35 
Male gender – no. (%) 593 (52) 261 (49) 332 (54) 0.12 
Risk factors – no. (%)     
Hypertension 811 (71) 365 (68) 446 (74) 0.07 
Hypercholesterolemia 397 (36) 177 (34) 220 (38) 0.23 
Diabetes 282 (25) 113 (21) 169 (28) 0.01 
Current smoking 236 (21) 108 (20) 128 (21) 0.90 
History of smoking 511 (45) 229 (43) 282 (46) 0.39 
History – no. (%)     
Coronary artery disease 415 (36) 162 (30) 253 (42) <0.001 
Previous MI 228 (21) 84 (16) 144 (25) 0.001 
Previous revascularization 232 (21) 94 (18) 138 (23) 0.03 
Peripheral artery disease 156 (14) 67 (13) 89 (15) 0.39 
Previous stroke 146 (13) 61 (11) 85 (14) 0.23 
ECG findings – no. (%)     
      ST-segment deviation 57 (5) 23 (4) 34 (6) 0.42 
      T-wave inversion 80 (7) 44 (8) 36 (6) 0.14 
      LBBB 62 (5) 18 (3) 44 (7) 0.01 
      RBBB+LAFB 48 (4) 7 (1) 41 (7) <0.001 
      RBBB 58 (5) 35 (7) 23 (4) 0.04 
      LAFB 39 (3) 2 (0) 37 (6) <0.001 
      LVH 215 (19) 109 (20) 106 (17) 0.18 
      Norm 729 (63) 363 (68) 366 (59) 0.003 
Adjudicated final diagnosis – 
no. (%) 
    
      AHF 704 (61) 292 (55) 412 (67) <0.001 
      Non-cardiac causes of 
dyspnea* 447 (39) 242 (45) 205 (33) <0.001 
Imaging Findings – no. (%)     
      LVEF 55 [35. 60] 55 [40. 60] 50 [34. 60] <0.001 
Laboratory findings     
BNP. ng/l 476 [117. 1148] 345 [85. 857] 605 [159. 1359] <0.001 
Chronic medication – no. (%)     
ASA 417 (37) 192 (37) 225 (38) 0.73 
Vitamin K antagonists 302 (27) 118 (22) 184 (31) 0.002 
B-blockers 532 (48) 234 (45) 298 (50) 0.07 
Statins 365 (33) 170 (32) 195 (33) 0.88 
ACEIs/ARBs 762 (67) 367 (69) 395 (65) 0.11 
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MI = myocardial infarction. ECG = electrocardiogram. LBBB = left bundle branch block. RBBB = 
right bundle branch block. LAFB = left anterior fascicular block. LVH = left ventricular hypertrophy. 
MPI = myocardial perfusion imaging. CHF = congestive heart failure. LVEF = left ventricular 
ejection fraction. BNP = B-type natriuretic peptide. ASA= Acetylsalicylic acid. ACEIs/ARBs = 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
*Non-cardiac causes of dyspnea included predefined categories such as chronic obstructive 
pulmonary disease (COPD), asthma bronchiale, pneumonia, bronchitis, Influenza, 
hyperventilation, pulmonary embolism or cancer.  
 
 
  
Calcium antagonists 319 (29) 149 (28) 170 (29) 0.87 
Nitrates 128 (12) 55 (11) 73 (13) 0.30 
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Table 3 Cox proportional hazard analysis for all-cause mortality at 360 days 
 Univariable cox regression  Multivariable cox regression 
 Hazard ratio 95% CI p-Value  Hazard ratio 95% CI p-Value 
QRS-score ≥ 3 1.48 1.16 1.89 .001  1.42 1.10 1.83 .006 
Gender (male) 1.08 0.85 1.36 0.53      
Age ≥ 70 (years) 2.90 2.10 4.02 < 0.001  2.60 1.85 3.65 < 0.001 
Diabetes mellitus 1.06 0.81 1.38 .68      
NYHA III (III vs. II) 1.97 1.11 3.51 .02  1.39 0.78 2.49 .27 
NYHA IV (IV vs. II) 3.30 1.88 5.81 < 0.001  2.37 1.34 4.20 0.003 
Atrial Fibrillation  1.31 1.02 1.69 .04  0.96 0.73 1.26 .77 
QRS-width (ms) 1.30 0.99 1.70 .06      
High creatinine (≥105 mol/l)  2.25 1.78 2.86 < 0.001  1.96 1.53 2.52 < 0.001 
LBBB 2.15 1.45 3.20 < 0.001  1.52 0.99 2.33 .05 
Heartrate ≥ 80 (bpm) 1.63 1.24 2.14 < 0.001  1.63 1.23 2.17 0.001 
*NYHA = New York Heart Association. LBBB = left bundle branch block.  BPM = beats per minute.
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Figure 1 
Boxplots for the distribution of the QRS-score according to the extent of 
myocardial scar on myocardial perfusion imaging. 
Figure 2 
Boxplots for the distribution of the QRS-score according to the left 
ventricular ejection fraction in (A) the BASEL VIII and in (B) the BASEL V 
cohort. 
Figure 3A 
Kaplan-Meier curves for all-cause mortality at 360 days displayed for QRS-
score levels <3 and ≥ 3 
Figure 3B 
Kaplan-Meier curves for cardiovascular re-hospitalization at 360 days 
displayed for QRS-score levels <3 and ≥ 3 
